New technologies in developing recombinant attenuated Salmonella vaccine vectors

Microbial Pathogenesis

Volumn 58, Issue , 2013, Pages 17-28

  Wang, Shifeng ^a   Kong, Qingke ^a   Curtiss, Roy ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Antigen synthesis; Biological containment; Delayed attenuation or attenuation; Delayed recombinant vaccines; Lipid A; O antigen; Salmonella; Vaccine

Indexed keywords

ADENYLOSUCCINATE LYASE; BACTERIAL VACCINE; BACTERIAL VECTOR; CD14 ANTIGEN; DSBA VACCINE; ELTB VACCINE; IMMUNOGLOBULIN G; LIPID A; LIVE VACCINE; LPP VACCINE; O ANTIGEN; OMPA VACCINE; PHOA VACCINE; PNEUMOCOCCAL SURFACE PROTEIN A; RECOMBINANT ATTENUATED SALMONELLA VACCINE VECTOR; SALMONELLOSIS VACCINE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GENE; BACTERIAL SECRETION SYSTEM; BIOTECHNOLOGICAL PROCEDURES; CHEMICAL MODIFICATION; DADB GENE; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; GALE GENE; GENE DOSAGE; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC COMPLEMENTATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; INFECTION PREVENTION; LPXE GENE; MICROBIAL ATTENUATION; NONHUMAN; PLASMID; PMI GENE; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PURINE SYNTHESIS; RFAH GENE; RFC GENE; SALMONELLOSIS; TYPHOID FEVER;

ANTIGENS, BACTERIAL; DRUG CARRIERS; DRUG DISCOVERY; GENE EXPRESSION REGULATION, BACTERIAL; GENETIC VECTORS; HUMANS; LIPID A; PNEUMOCOCCAL VACCINES; RECOMBINANT PROTEINS; SALMONELLA; SECRETORY VESICLES; STREPTOCOCCUS PNEUMONIAE; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

SALMONELLA; STREPTOCOCCUS PNEUMONIAE;

EID: 84875850160     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2012.10.006     Document Type: Article

References (191)

1. Curtiss R., Nakayama K., Kelly S.M. Recombinant avirulent Salmonella vaccine strains with stable maintenance and high level expression of cloned genes in vivo. Immunol Invest 1989, 18:583-596.
2. + expression-cloning vector: stable maintenance and high level expression of cloned genes in a Salmonella vaccine strain. Nat Biotechnol 1988, 6:693-697.
3. Curtiss R., Kelly S.M., Gulig P.A., Nakayama K. Selective delivery of antigens by recombinant bacteria. Curr Top Microbiol Immunol 1989, 146:35-49.
4. Curtiss R., Kelly S.M., Gulig P.A., Nakayama K. Stable recombinant avirulent Salmonella vaccine strains. Adv Exp Med Biol 1989, 251:33-47.
5. Moon J.J., McSorley S.J. Tracking the dynamics of Salmonella specific T cell responses. Curr Top Microbiol Immunol 2009, 334:179-198.
6. Srinivasan A., McSorley S.J. Activation of Salmonella-specific immune responses in the intestinal mucosa. Arch Immunol Ther Exp (Warsz) 2006, 54:25-31.
7. Griffin A.J., McSorley S.J. Development of protective immunity to Salmonella, a mucosal pathogen with a systemic agenda. Mucosal Immunol 2011, 4:371-382.
8. Broz P., Ohlson M.B., Monack D.M. Innate immune response to Salmonella typhimurium, a model enteric pathogen. Gut Microbe 2012, 3:62-70.
9. Tam M.A., Rydstrom A., Sundquist M., Wick M.J. Early cellular responses to Salmonella infection: dendritic cells, monocytes, and more. Immunol Rev 2008, 225:140-162.
10. Agbor T.A., McCormick B.A. Salmonella effectors: important players modulating host cell function during infection. Cell Microbiol 2011, 13:1858-1869.
11. Dean P. Functional domains and motifs of bacterial type III effector proteins and their roles in infection. FEMS Microbiol Rev 2011, 35:1100-1125.
12. Ibarra J.A., Steele-Mortimer O. Salmonella-the ultimate insider. Salmonella virulence factors that modulate intracellular survival. Cell Microbiol 2009, 11:1579-1586.
13. Malik-Kale P., Jolly C.E., Lathrop S., Winfree S., Luterbach C., Steele-Mortimer O. Salmonella - at home in the host cell. Front Microbiol 2011, 2:125.
14. Curtiss R., Xin W., Li Y., Kong W., Wanda S.Y., Gunn B., et al. New technologies in using recombinant attenuated Salmonella vaccine vectors. Crit Rev Immunol 2010, 30:255-270.
15. Hegazy W.A., Hensel M. Salmonella enterica as a vaccine carrier. Future Microbiol 2012, 7:111-127.
16. Simon R., Tennant S.M., Galen J.E., Levine M.M. Mouse models to assess the efficacy of non-typhoidal Salmonella vaccines: revisiting the role of host innate susceptibility and routes of challenge. Vaccine 2011, 29:5094-5106.
17. Moreno M., Kramer M.G., Yim L., Chabalgoity J.A. Salmonella as live trojan horse for vaccine development and cancer gene therapy. Curr Gene Ther 2010, 10:56-76.
18. Shahabi V., Maciag P.C., Rivera S., Wallecha A. Live, attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment. Bioeng Bugs 2010, 1:235-243.
19. Paterson Y., Guirnalda P.D., Wood L.M. Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy. Semin Immunol 2010, 22:183-189.
20. Galen J.E., Pasetti M.F., Tennant S., Ruiz-Olvera P., Sztein M.B., Levine M.M. Salmonella enterica serovar Typhi live vector vaccines finally come of age. Immunol Cell Biol 2009, 87:400-412.
21. Paterson G.K., Maskell D.J. Recent advances in the field of Salmonella Typhi vaccines. Hum Vaccin 2010, 6:379-384.
22. Marathe S.A., Lahiri A., Negi V.D., Chakravortty D. Typhoid fever & vaccine development: a partially answered question. Indian J Med Res 2012, 135:161-169.
23. O'Brien K.L., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374:893-902.
24. Curtiss R., Wanda S.Y., Gunn B.M., Zhang X., Tinge S.A., Ananthnarayan V., et al. Salmonella enterica serovar Typhimurium strains with regulated delayed attenuation in vivo. Infect Immun 2009, 77:1071-1082.
25. Germanier R., Furer E. Immunity in experimental salmonellosis. II. Basis for the avirulence and protective capacity of gal E mutants of Salmonella typhimurium. Infect Immun 1971, 4:663-673.
26. Collins L.V., Attridge S., Hackett J. Mutations at rfc or pmi attenuate Salmonella typhimurium virulence for mice. Infect Immun 1991, 59:1079-1085.
27. Kong W., Wanda S.Y., Zhang X., Bollen W., Tinge S.A., Roland K.L., et al. Regulated programmed lysis of recombinant Salmonella in host tissues to release protective antigens and confer biological containment. Proc Natl Acad Sci U S A 2008, 105:9361-9366.
28. Kong Q., Liu Q., Jansen A.M., Curtiss R. Regulated delayed expression of rfc enhances the immunogenicity and protective efficacy of a heterologous antigen delivered by live attenuated Salmonella enterica vaccines. Vaccine 2010, 28:6094-6103.
29. Kong Q., Liu Q., Roland K.L., Curtiss R. Regulated delayed expression of rfaH in an attenuated Salmonella enterica serovar Typhimurium vaccine enhances immunogenicity of outer membrane proteins and a heterologous antigen. Infect Immun 2009, 77:5572-5582.
30. Kong Q., Six D.A., Roland K.L., Liu Q., Gu L., Reynolds C.M., et al. Salmonella synthesizing 1-dephosphorylated lipopolysaccharide exhibits low endotoxic activity while retaining its immunogenicity. J Immunol 2011, 187:412-423.
31. Fields P.I., Swanson R.V., Haidaris C.G., Heffron F. Mutants of Salmonella typhimurium that cannot survive within the macrophage are avirulent. Proc Natl Acad Sci U S A 1986, 83:5189-5193.
32. Finlay B.B., Brumell J.H. Salmonella interactions with host cells: in vitro to in vivo. Philos Trans R Soc Lond B Biol Sci 2000, 355:623-631.
33. Reeves P. Role of O-antigen variation in the immune response. Trends Microbiol 1995, 3:381-386.
34. Rowley D. Sensitivity of rough gram-negative bacteria to the bactericidal action of serum. J Bacteriol 1968, 95:1647-1650.
35. Nnalue N.A., Lindberg A.A. Salmonella choleraesuis strains deficient in O antigen remain fully virulent for mice by parenteral inoculation but are avirulent by oral administration. Infect Immun 1990, 58:2493-2501.
36. Roantree R.J. The relationship of lipopolysaccahride structure to bacterial virulence. Microbial toxins 1971, 1-37. Academic Press, New York. G. Weinbaum, S. Kadis, S. Ajl (Eds.).
37. Finlay B.B., Starnbach M.N., Francis C.L., Stocker B.A., Chatfield S., Dougan G., et al. Identification and characterization of TnphoA mutants of Salmonella that are unable to pass through a polarized MDCK epithelial cell monolayer. Mol Microbiol 1988, 2:757-766.
38. Stone B.J., Garcia C.M., Badger J.L., Hassett T., Smith R.I., Miller V.L. Identification of novel loci affecting entry of Salmonella enteritidis into eukaryotic cells. J Bacteriol 1992, 174:3945-3952.
39. Muotiala A., Hovi M., Makela P.H. Protective immunity in mouse salmonellosis: comparison of smooth and rough live and killed vaccines. Microb Pathog 1989, 6:51-60.
40. Smith H.W. The use of live vaccines in experimental Salmonella gallinarum infection in chickens with observations on their interference effect. J Hyg (Lond) 1956, 54:419-432.
41. Germanier R., Fuer E. Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J Infect Dis 1975, 131:553-558.
42. Kong Q., Yang J., Liu Q., Alamuri P., Roland K.L., Curtiss R. Effect of deletion of genes involved in lipopolysaccharide core and O-antigen synthesis on virulence and immunogenicity of Salmonella enterica serovar Typhimurium. Infect Immun 2011, 79:4227-4239.
43. BAD promoter. J Bacteriol 1995, 177:4121-4130.
44. Collins L.V., Hackett J. Molecular cloning, characterization, and nucleotide sequence of the rfc gene, which encodes an O-antigen polymerase of Salmonella typhimurium. J Bacteriol 1991, 173:2521-2529.
45. Bailey M.J., Hughes C., Koronakis V. RfaH and the ops element, components of a novel system controlling bacterial transcription elongation. Mol Microbiol 1997, 26:845-851.
46. Lindberg A.A., Hellerqvist C.G. Rough mutants of Salmonella typhimurium: immunochemical and structural analysis of lipopolysaccharides from rfaH mutants. J Gen Microbiol 1980, 116:25-32.
47. Nagy G., Dobrindt U., Hacker J., Emody L. Oral immunization with an rfaH mutant elicits protection against salmonellosis in mice. Infect Immun 2004, 72:4297-4301.
48. Nagy G., Danino V., Dobrindt U., Pallen M., Chaudhuri R., Emody L., et al. Down-regulation of key virulence factors makes the Salmonella enterica serovar Typhimurium rfaH mutant a promising live-attenuated vaccine candidate. Infect Immun 2006, 74:5914-5925.
49. Nagy G., Dobrindt U., Schneider G., Khan A.S., Hacker J., Emody L. Loss of regulatory protein RfaH attenuates virulence of uropathogenic Escherichia coli. Infect Immun 2002, 70:4406-4413.
50. Galen J.E., Simon R., Ernst R.K. Salmonella expressing detoxified lipopolysaccharide is immunogenic and protective both as an attenuated vaccine and for delivery of foreign antigens. Expert Rev Vacc 2011, 10:1679-1682.
51. Dilts D.A., Riesenfeld-Orn I., Fulginiti J.P., Ekwall E., Granert C., Nonenmacher J., et al. Phase I clinical trials of aroA aroD and aroA aroD htrA attenuated S. typhi vaccines; effect of formulation on safety and immunogenicity. Vaccine 2000, 18:1473-1484.
52. Tacket C.O., Hone D.M., Curtiss R., Kelly S.M., Losonsky G., Guers L., et al. Comparison of the safety and immunogenicity of ΔaroC ΔaroD and Δcya Δcrp Salmonella typhi strains in adult volunteers. Infect Immun 1992, 60:536-541.
53. Nardelli-Haefliger D., Kraehenbuhl J.P., Curtiss R., Schodel F., Potts A., Kelly S., et al. Oral and rectal immunization of adult female volunteers with a recombinant attenuated Salmonella typhi vaccine strain. Infect Immun 1996, 64:5219-5224.
54. Hone D.M., Attridge S.R., Forrest B., Morona R., Daniels D., LaBrooy J.T., et al. A galE via (Vi antigen-negative) mutant of Salmonella typhi Ty2 retains virulence in humans. Infect Immun 1988, 56:1326-1333.
55. Curtiss R., Kelly S.M. Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. Infect Immun 1987, 55:3035-3043.
56. Jones P.W., Dougan G., Hayward C., Mackensie N., Collins P., Chatfield S.N. Oral vaccination of calves against experimental salmonellosis using a double aro mutant of Salmonella typhimurium. Vaccine 1991, 9:29-34.
57. Smith B.P., Reina-Guerra M., Stocker B.A., Hoiseth S.K., Johnson E.H. Vaccination of calves against Salmonella dublin with aromatic-dependent Salmonella typhimurium. Am J Vet Res 1984, 45:1858-1861.
58. Smith B.P., Reina-Guerra M., Hoiseth S.K., Stocker B.A., Habasha F., Johnson E., et al. Aromatic-dependent Salmonella typhimurium as modified live vaccines for calves. Am J Vet Res 1984, 45:59-66.
59. Levine M.M., Herrington D., Murphy J.R., Morris J.G., Losonsky G., Tall B., et al. Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans. J Clin Invest 1987, 79:888-902.
60. Hohmann E.L., Oletta C.A., Miller S.I. Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers. Vaccine 1996, 14:19-24.
61. Ameiss K., Ashraf S., Kong W., Pekosz A., Wu W.H., Milich D., et al. Delivery of woodchuck hepatitis virus-like particle presented influenza M2e by recombinant attenuated Salmonella displaying a delayed lysis phenotype. Vaccine 2010, 28:6704-6713.
62. Ashraf S., Kong W., Wang S., Yang J., Curtiss R. Protective cellular responses elicited by vaccination with influenza nucleoprotein delivered by a live recombinant attenuated Salmonella vaccine. Vaccine 2011, 29:3990-4002.
63. Rietschel E.T., Galanos C. Lipid A antiserum-mediated protection against lipopolysaccharide- and lipid A-induced fever and skin necrosis. Infect Immun 1977, 15:34-49.
64. Raetz C.R., Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem 2002, 71:635-700.
65. Raetz C.R., Reynolds C.M., Trent M.S., Bishop R.E. Lipid A modification systems in gram-negative bacteria. Annu Rev Biochem 2007, 76:295-329.
66. Miller S.I., Ernst R.K., Bader M.W. LPS, TLR4 and infectious disease diversity. Nat Rev Microbiol 2005, 3:36-46.
67. Lu Y.C., Yeh W.C., Ohashi P.S. LPS/TLR4 signal transduction pathway. Cytokine 2008, 42:145-151.
68. Miyake K. Roles for accessory molecules in microbial recognition by Toll-like receptors. J Endotoxin Res 2006, 12:195-204.
69. Takeda K., Akira S. TLR signaling pathways. Semin Immunol 2004, 16:3-9.
70. Mata-Haro V., Cekic C., Martin M., Chilton P.M., Casella C.R., Mitchell T.C. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007, 316:1628-1632.
71. Kagan J.C., Su T., Horng T., Chow A., Akira S., Medzhitov R. TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-β. Nat Immunol 2008, 9:361-368.
72. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140:805-820.
73. Park B.S., Song D.H., Kim H.M., Choi B.S., Lee H., Lee J.O. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009, 458:1191-1195.
74. Rietschel E.T., Kirikae T., Schade F.U., Mamat U., Schmidt G., Loppnow H., et al. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J 1994, 8:217-225.
75. Rietschel E.T., Kirikae T., Schade F.U., Ulmer A.J., Holst O., Brade H., et al. The chemical structure of bacterial endotoxin in relation to bioactivity. Immunobiology 1993, 187:169-190.
76. Reed S.G., Bertholet S., Coler R.N., Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009, 30:23-32.
77. Dofferhoff A.S., Nijland J.H., de Vries-Hospers H.G., Mulder P.O., Weits J., Bom V.J. Effects of different types and combinations of antimicrobial agents on endotoxin release from gram-negative bacteria: an in-vitro and in-vivo study. Scand J Infect Dis 1991, 23:745-754.
78. Evans M.E., Pollack M. Effect of antibiotic class and concentration on the release of lipopolysaccharide from Escherichia coli. J Infect Dis 1993, 167:1336-1343.
79. Elson G., Dunn-Siegrist I., Daubeuf B., Pugin J. Contribution of Toll-like receptors to the innate immune response to Gram-negative and Gram-positive bacteria. Blood 2007, 109:1574-1583.
80. Roger T., Froidevaux C., Le Roy D., Reymond M.K., Chanson A.L., Mauri D., et al. Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4. Proc Natl Acad Sci U S A 2009, 106:2348-2352.
81. Morrison D.C., Silverstein R., Luchi M., Shnyra A. Structure-function relationships of bacterial endotoxins. Contribution to microbial sepsis. Infect Dis Clin North Am 1999, 13:313-340.
82. Wang X., Karbarz M.J., McGrath S.C., Cotter R.J., Raetz C.R. MsbA transporter-dependent lipid A 1-dephosphorylation on the periplasmic surface of the inner membrane: topography of Francisella novicida LpxE expressed in Escherichia coli. J Biol Chem 2004, 279:49470-49478.
83. Kong Q., Six D.A., Liu Q., Gu L., Roland K.L., Raetz C.R., et al. Palmitoylation state impacts induction of innate and acquired immunity by the Salmonella enterica serovar Typhimurium msbB mutant. Infect Immun 2011, 79:5027-5038.
84. Kong Q., Six D.A., Liu Q., Gu L., Wang S., Alamuri P., et al. Phosphate groups of Lipid A are essential for Salmonella enterica serovar Typhimurium virulence and affect innate and adaptive immunity. Infect Immun 2012, 80:3215-3224.
85. Clementz T., Zhou Z., Raetz C.R. Function of the Escherichia coli msbB gene, a multicopy suppressor of htrB knockouts, in the acylation of lipid A. J Biol Chem 1997, 272:10353-10360.
86. McKelvie N.D., Khan S.A., Karavolos M.H., Bulmer D.M., Lee J.J., DeMarco R., et al. Genetic detoxification of an aroA Salmonella enterica serovar Typhimurium vaccine strain does not compromise protection against virulent Salmonella and enhances the immune responses towards a protective malarial antigen. FEMS Immunol Med Microbiol 2008, 52:237-246.
87. Bone R.C. Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome). JAMA 1992, 268:3452-3455.
88. Dinarello C.A., Gelfand J.A., Wolff S.M. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 1993, 269:1829-1835.
89. Low K.B., Ittensohn M., Le T., Platt J., Sodi S., Amoss M., et al. Lipid A mutant Salmonella with suppressed virulence and TNF-α induction retain tumor-targeting in vivo. Nat Biotechnol 1999, 17:37-41.
90. Toso J.F., Gill V.J., Hwu P., Marincola F.M., Restifo N.P., Schwartzentruber D.J., et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 2002, 20:142-152.
91. reg) cell expression in mice: the critical role of lipopolysaccharide and Braun lipoprotein in modulating tumor growth. Cancer Gene Ther 2010, 17:97-108.
92. Luo X., Li Z., Lin S., Le T., Ittensohn M., Bermudes D., et al. Antitumor effect of VNP20009, an attenuated Salmonella, in murine tumor models. Oncol Res 2001, 12:501-508.
93. Germanier R., Furer E. Characteristics of the attenuated oral vaccine strain " S. typhi" Ty 21a. Dev Biol Stand 1983, 53:3-7.
94. Kopecko D.J., Sieber H., Ures J.A., Furer A., Schlup J., Knof U., et al. Genetic stability of vaccine strain Salmonella Typhi Ty21a over 25 years. Int J Med Microbiol 2009, 299:233-246.
95. Zhang X.L., Jeza V.T., Pan Q. Salmonella typhi: from a human pathogen to a vaccine vector. Cell Mol Immunol 2008, 5:91-97.
96. Garmory H.S., Brown K.A., Titball R.W. Salmonella vaccines for use in humans: present and future perspectives. FEMS Microbiol Rev 2002, 26:339-353.
97. Li Y., Wang S., Scarpellini G., Gunn B., Xin W., Wanda S.Y., et al. Evaluation of new generation Salmonella enterica serovar Typhimurium vaccines with regulated delayed attenuation to induce immune responses against PspA. Proc Natl Acad Sci U S A 2009, 106:593-598.
98. Shi H., Santander J., Brenneman K.E., Wanda S.Y., Wang S., Senechal P., et al. Live recombinant Salmonella Typhi vaccines constructed to investigate the role of rpoS in eliciting immunity to a heterologous antigen. PLoS One 2010, 5:e11142.
99. Curtiss R., Zhang X., Wanda S.Y., Kang H.Y., Konjufca V., Li Y., et al. Induction of host immune responses using Salmonella-vectored vaccines. Virulence mechanisms of bacterial pathogens 2007, 297-313. ASM Press, Washington D.C. 4th ed. K.A. Brogden, F.C. Minion, N. Cornick, T.B. Stanton, Q. Zhang, L.K. Nolan (Eds.).
100. Bollen W.S., Gunn B.M., Mo H., Lay M.K., Curtiss R. Presence of wild-type and attenuated Salmonella enterica strains in brain tissues following inoculation of mice by different routes. Infect Immun 2008, 76:3268-3272.
101. Li Y., Wang S., Xin W., Scarpellini G., Shi Z., Gunn B., et al. A sopB deletion mutation enhances the immunogenicity and protective efficacy of a heterologous antigen delivered by live attenuated Salmonella enterica vaccines. Infect Immun 2008, 76:5238-5246.
102. Wang S., Li Y., Scarpellini G., Kong W., Shi H., Baek C.H., et al. Salmonella vaccine vectors displaying delayed antigen synthesis in vivo to enhance immunogenicity. Infect Immun 2010, 78:3969-3980.
103. Wang S., Li Y., Shi H., Scarpellini G., Torres-Escobar A., Roland K.L., et al. Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine. Infect Immun 2010, 78:3258-3271.
104. Wang S., Li Y., Shi H., Sun W., Roland K.L., Curtiss R. Comparison of a regulated delayed antigen synthesis system with in vivo-inducible promoters for antigen delivery by live attenuated Salmonella vaccines. Infect Immun 2011, 79:937-949.
105. Sizemore D., Warner E., Lawrence J., Thomas L.J., Roland K., Killeen K. Construction and screening of attenuated ΔphoP/Q Salmonella typhimurium vectored plague vaccine candidates. Hum Vaccin Immunother 2012, 8.
106. Roland K.L., Cloninger C., Kochi S.K., Thomas L.J., Tinge S.A., Rouskey C., et al. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli. Vaccine 2007, 25:8574-8584.
107. Ryan E.T., Crean T.I., Kochi S.K., John M., Luciano A.A., Killeen K.P., et al. Development of a ΔglnA balanced lethal plasmid system for expression of heterologous antigens by attenuated vaccine vector strains of Vibrio cholerae. Infect Immun 2000, 68:221-226.
108. Schoen C., Loeffler D.I., Frentzen A., Pilgrim S., Goebel W., Stritzker J. Listeria monocytogenes as novel carrier system for the development of live vaccines. Int J Med Microbiol 2008, 298:45-58.
109. Hagg P., de Pohl J.W., Abdulkarim F., Isaksson L.A. A host/plasmid system that is not dependent on antibiotics and antibiotic resistance genes for stable plasmid maintenance in Escherichia coli. J Biotechnol 2004, 111:17-30.
110. Ross P., O'Gara F., Condon S. Thymidylate synthase gene from Lactococcus lactis as a genetic marker: an alternative to antibiotic resistance genes. Appl Environ Microbiol 1990, 56:2164-2169.
111. Mahan M.J., Slauch J.M., Mekalanos J.J. Selection of bacterial virulence genes that are specifically induced in host tissues. Science 1993, 259:686-688.
112. Sorensen K.I., Larsen R., Kibenich A., Junge M.P., Johansen E. A food-grade cloning system for industrial strains of Lactococcus lactis. Appl Environ Microbiol 2000, 66:1253-1258.
113. Galán J.E., Nakayama K., Curtiss R. Cloning and characterization of the asd gene of Salmonella typhimurium: use in stable maintenance of recombinant plasmids in Salmonella vaccine strains. Gene 1990, 94:29-35.
114. Curtiss R. Bacterial infectious disease control by vaccine development. J Clin Invest 2002, 110:1061-1066.
115. + dual-plasmid system offers a novel means to deliver multiple protective antigens by a recombinant attenuated Salmonella vaccine. Infect Immun 2012, 80:3621-3633.
116. Galakatos N.G., Daub E., Botstein D., Walsh C.T. Biosynthetic alr alanine racemase from Salmonella typhimurium: DNA and protein sequence determination. Biochemistry 1986, 25:3255-3260.
117. Wasserman S.A., Walsh C.T., Botstein D. Two alanine racemase genes in Salmonella typhimurium that differ in structure and function. J Bacteriol 1983, 153:1439-1450.
118. Badet B., Roise D., Walsh C.T. Inactivation of the dadB Salmonella typhimurium alanine racemase by D and L isomers of beta-substituted alanines: kinetics, stoichiometry, active site peptide sequencing, and reaction mechanism. Biochemistry 1984, 23:5188-5194.
119. Galakatos N.G., Walsh C.T. Mutations at the interdomain hinge region of the DadB alanine racemase: effects of length and conformational constraint of the linker sequence on catalytic efficiency. Biochemistry 1989, 28:8167-8174.
120. Tauch A., Gotker S., Puhler A., Kalinowski J., Thierbach G. The alanine racemase gene alr is an alternative to antibiotic resistance genes in cloning systems for industrial Corynebacterium glutamicum strains. J Biotechnol 2002, 99:79-91.
121. Galen J.E., Wang J.Y., Chinchilla M., Vindurampulle C., Vogel J.E., Levy H., et al. A new generation of stable, nonantibiotic, low-copy-number plasmids improves immune responses to foreign antigens in Salmonella enterica serovar Typhi live vectors. Infect Immun 2010, 78:337-347.
122. Kang H.Y., Srinivasan J., Curtiss R. Immune responses to recombinant pneumococcal PspA antigen delivered by live attenuated Salmonella enterica serovar Typhimurium vaccine. Infect Immun 2002, 70:1739-1749.
123. Galen J.E., Nair J., Wang J.Y., Wasserman S.S., Tanner M.K., Sztein M.B., et al. Optimization of plasmid maintenance in the attenuated live vector vaccine strain Salmonella typhi CVD 908-htrA. Infect Immun 1999, 67:6424-6433.
124. Gerdes K. The parB (hok/sok) locus of plasmid R1: a general purpose plasmid stabilization system. Bio/Technology 1988, 6:1402-1405.
125. Jensen R.B., Gerdes K. Programmed cell death in bacteria: proteic plasmid stabilization systems. Mol Microbiol 1995, 17:205-210.
126. Yamaguchi Y., Park J.H., Inouye M. Toxin-antitoxin systems in bacteria and archaea. Annu Rev Genet 2011, 45:61-79.
127. Yamaguchi Y., Inouye M. Regulation of growth and death in Escherichia coli by toxin-antitoxin systems. Nat Rev Microbiol 2011, 9:779-790.
128. Vandermeulen G., Marie C., Scherman D., Preat V. New generation of plasmid backbones devoid of antibiotic resistance marker for gene therapy trials. Mol Ther 2011, 19:1942-1949.
129. Xin W., Li Y., Mo H., Roland K.L., Curtiss R. PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae. Infect Immun 2009, 77:4518-4528.
130. Cohen A., Laban A. Plasmidic recombination in Escherichia coli K-12: the role of recF gene function. Mol Gen Genet 1983, 189:471-474.
131. Kolodner R., Fishel R.A., Howard M. Genetic recombination of bacterial plasmid DNA: effect of RecF pathway mutations on plasmid recombination in Escherichia coli. J Bacteriol 1985, 163:1060-1066.
132. Zhang X., Wanda S.Y., Brenneman K., Kong W., Roland K., Curtiss R. Improving Salmonella vector with rec mutation to stabilize the DNA cargoes. BMC Microbiol 2011, 11:31.
133. Gentschev I., Dietrich G., Goebel W. The E. coli α-hemolysin secretion system and its use in vaccine development. Trends Microbiol 2002, 10:39-45.
134. Hohmann E.L., Oletta C.A., Loomis W.P., Miller S.I. Macrophage-inducible expression of a model antigen in Salmonella typhimurium enhances immunogenicity. Proc Natl Acad Sci U S A 1995, 92:2904-2908.
135. Chatfield S.N., Charles I.G., Makoff A.J., Oxer M.D., Dougan G., Pickard D., et al. Use of the nirB promoter to direct the stable expression of heterologous antigens in Salmonella oral vaccine strains: development of a single-dose oral tetanus vaccine. Biotechnology (N Y) 1992, 10:888-892.
136. Marshall D.G., Haque A., Fowler R., Del Guidice G., Dorman C.J., Dougan G., et al. Use of the stationary phase inducible promoters, spv and dps, to drive heterologous antigen expression in Salmonella vaccine strains. Vaccine 2000, 18:1298-1306.
137. Aizenman E., Engelberg-Kulka H., Glaser G. An Escherichia coli chromosomal " addiction module" regulated by guanosine 3',5'-bispyrophosphate: a model for programmed bacterial cell death. Proc Natl Acad Sci U S A 1996, 93:6059-6063.
138. Christensen S.K., Pedersen K., Hansen F.G., Gerdes K. Toxin-antitoxin loci as stress-response-elements: ChpAK/MazF and ChpBK cleave translated RNAs and are counteracted by tmRNA. J Mol Biol 2003, 332:809-819.
139. Zhang Y., Zhang J., Hara H., Kato I., Inouye M. Insights into the mRNA cleavage mechanism by MazF, an mRNA interferase. J Biol Chem 2005, 280:3143-3150.
140. Suzuki M., Zhang J., Liu M., Woychik N.A., Inouye M. Single protein production in living cells facilitated by an mRNA interferase. Mol Cell 2005, 18:253-261.
141. Suzuki M., Mao L., Inouye M. Single protein production (SPP) system in Escherichia coli. Nat Protoc 2007, 2:1802-1810.
142. Mao L., Inouye M. Use of E. coli for the production of a single protein. Methods Mol Biol 2012, 899:177-185.
143. Shimazu T., Degenhardt K., Nur E.K.A., Zhang J., Yoshida T., Zhang Y., et al. NBK/BIK antagonizes MCL-1 and BCL-XL and activates BAK-mediated apoptosis in response to protein synthesis inhibition. Genes Dev 2007, 21:929-941.
144. Kang H.Y., Curtiss R. Immune responses dependent on antigen location in recombinant attenuated Salmonella typhimurium vaccines following oral immunization. FEMS Immunol Med Microbiol 2003, 37:99-104.
145. Osorio M., Wu Y., Singh S., Merkel T.J., Bhattacharyya S., Blake M.S., et al. Anthrax protective antigen delivered by Salmonella enterica serovar Typhi Ty21a protects mice from a lethal anthrax spore challenge. Infect Immun 2009, 77:1475-1482.
146. Hotz C., Fensterle J., Goebel W., Meyer S.R., Kirchgraber G., Heisig M., et al. Improvement of the live vaccine strain Salmonella enterica serovar Typhi Ty21a for antigen delivery via the hemolysin secretion system of Escherichia coli. Int J Med Microbiol 2009, 299:109-119.
147. Galen J.E., Zhao L., Chinchilla M., Wang J.Y., Pasetti M.F., Green J., et al. Adaptation of the endogenous Salmonella enterica serovar Typhi clyA-encoded hemolysin for antigen export enhances the immunogenicity of anthrax protective antigen domain 4 expressed by the attenuated live-vector vaccine strain CVD 908-htrA. Infect Immun 2004, 72:7096-7106.
148. Provence D.L., Curtiss R. Isolation and characterization of a gene involved in hemagglutination by an avian pathogenic Escherichia coli strain. Infect Immun 1994, 62:1369-1380.
149. Buddenborg C., Daudel D., Liebrecht S., Greune L., Humberg V., Schmidt M.A. Development of a tripartite vector system for live oral immunization using a gram-negative probiotic carrier. Int J Med Microbiol 2008, 298:105-114.
150. Rüssmann H., Shams H., Poblete F., Fu Y., Galán J.E., Donis R.Q. Delivery of epitopes by the Salmonella type III secretion system for vaccine development. Science 1998, 281:565-568.
151. Rüssmann H., Igwe E.I., Sauer J., Hardt W.D., Bubert A., Geginat G. Protection against murine listeriosis by oral vaccination with recombinant Salmonella expressing hybrid Yersinia type III proteins. J Immunol 2001, 167:357-365.
152. + memory T cells and long lasting protection following immunization with Salmonella typhimurium expressing a lymphocytic choriomeningitis MHC class I-restricted epitope. Vaccine 2001, 20:577-585.
153. Xin W., Wanda S.Y., Li Y., Wang S., Mo H., Curtiss R. Analysis of type II secretion of recombinant pneumococcal PspA and PspC in a Salmonella enterica serovar Typhimurium vaccine with regulated delayed antigen synthesis. Infect Immun 2008, 76:3241-3254.
154. Zekarias B., Mo H., Curtiss R. Recombinant attenuated Salmonella enterica serovar typhimurium expressing the carboxy-terminal domain of alpha toxin from Clostridium perfringens induces protective responses against necrotic enteritis in chickens. Clin Vacc Immunol 2008, 15:805-816.
155. Alaniz R.C., Deatherage B.L., Lara J.C., Cookson B.T. Membrane vesicles are immunogenic facsimiles of Salmonella typhimurium that potently activate dendritic cells, prime B and T cell responses, and stimulate protective immunity in vivo. J Immunol 2007, 179:7692-7701.
156. Marzoa J., Sanchez S., Costoya L., Dieguez-Casal E., Freixeiro P., Brookes C., et al. Induction of immune responses by purified outer membrane protein complexes from Neisseria meningitidis. Vaccine 2012, 30:2387-2395.
157. Gorringe A.R., Taylor S., Brookes C., Matheson M., Finney M., Kerr M., et al. Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Clin Vacc Immunol 2009, 16:1113-1120.
158. Dull P.M., McIntosh E.D. Meningococcal vaccine development-from glycoconjugates against MenACWY to proteins against MenB-potential for broad protection against meningococcal disease. Vaccine 2012, 30(Suppl. 2):B18-B25.
159. Nakao R., Hasegawa H., Ochiai K., Takashiba S., Ainai A., Ohnishi M., et al. Outer membrane vesicles of Porphyromonas gingivalis elicit a mucosal immune response. PLoS One 2011, 6:e26163.
160. Roier S., Leitner D.R., Iwashkiw J., Schild-Prufert K., Feldman M.F., Krohne G., et al. Intranasal immunization with nontypeable Haemophilus influenzae outer membrane vesicles induces cross-protective immunity in mice. PLoS One 2012, 7:e42664.
161. Avila-Calderon E.D., Lopez-Merino A., Jain N., Peralta H., Lopez-Villegas E.O., Sriranganathan N., et al. Characterization of outer membrane vesicles from Brucella melitensis and protection induced in mice. Clin Dev Immunol 2012, 2012:352493.
162. Bishop A.L., Tarique A.A., Patimalla B., Calderwood S.B., Qadri F., Camilli A. Immunization of mice with Vibrio cholerae outer-membrane vesicles protects against hyperinfectious challenge and blocks transmission. J Infect Dis 2012, 205:412-421.
163. Bishop A.L., Schild S., Patimalla B., Klein B., Camilli A. Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motility. Infect Immun 2010, 78:4402-4420.
164. Camacho A.I., de Souza J., Sanchez-Gomez S., Pardo-Ros M., Irache J.M., Gamazo C. Mucosal immunization with Shigella flexneri outer membrane vesicles induced protection in mice. Vaccine 2011, 29:8222-8229.
165. Nieves W., Asakrah S., Qazi O., Brown K.A., Kurtz J., Aucoin D.P., et al. A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection. Vaccine 2011, 29:8381-8389.
166. Park S.B., Jang H.B., Nho S.W., Cha I.S., Hikima J., Ohtani M., et al. Outer membrane vesicles as a candidate vaccine against edwardsiellosis. PLoS One 2011, 6:e17629.
167. Pierson T., Matrakas D., Taylor Y.U., Manyam G., Morozov V.N., Zhou W., et al. Proteomic characterization and functional analysis of outer membrane vesicles of Francisella novicida suggests possible role in virulence and use as a vaccine. J Proteome Res 2011, 10:954-967.
168. Collins B.S. Gram-negative outer membrane vesicles in vaccine development. Discov Med 2011, 12:7-15.
169. Muralinath M., Kuehn M.J., Roland K.L., Curtiss R. Immunization with Salmonella enterica serovar Typhimurium-derived outer membrane vesicles delivering the pneumococcal protein PspA confers protection against challenge with Streptococcus pneumoniae. Infect Immun 2011, 79:887-894.
170. Aghasadeghi M.R., Salmani A.S., Sadat S.M., Javadi F., Memarnejadian A., Vahabpour R., et al. Application of outer membrane vesicle of Neisseria meningitidis serogroup B as a new adjuvant to induce strongly Th1-oriented responses against HIV-1. Curr HIV Res 2011, 9:630-635.
171. Chen D.J., Osterrieder N., Metzger S.M., Buckles E., Doody A.M., DeLisa M.P., et al. Delivery of foreign antigens by engineered outer membrane vesicle vaccines. Proc Natl Acad Sci U S A 2010, 107:3099-3104.
172. Sanders H., Feavers I.M. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines. Expert Rev Vacc 2011, 10:323-334.
173. Asensio C.J., Gaillard M.E., Moreno G., Bottero D., Zurita E., Rumbo M., et al. Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate. Vaccine 2011, 29:1649-1656.
174. Lee S.R., Kim S.H., Jeong K.J., Kim K.S., Kim Y.H., Kim S.J., et al. Multi-immunogenic outer membrane vesicles derived from an MsbB-deficient Salmonella enterica serovar Typhimurium mutant. J Microbiol Biotechnol 2009, 19:1271-1279.
175. van der Ley P., van den Dobbelsteen G. Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants. Hum Vaccin 2011, 7:886-890.
176. Riquelme S.A., Wozniak A., Kalergis A.M., Bueno S.M. Evasion of host immunity by virulent Salmonella: implications for vaccine design. Curr Med Chem 2011, 18:5666-5675.
177. Link C., Ebensen T., Standner L., Dejosez M., Reinhard E., Rharbaoui F., et al. An SopB-mediated immune escape mechanism of Salmonella enterica can be subverted to optimize the performance of live attenuated vaccine carrier strains. Microbes Infect 2006, 8:2262-2269.
178. Curtiss R., Pereira D.A., Hsu J.C., Hull S.C., Clark J.E., Maturin L.J., et al. Biological containment: the subordination of Escherichia coil K-12. Recombinant molecules: impact on science and society 1976, 45-56. Raven Press, New York. R.F. Beers, E.G. Bassett (Eds.).
179. Levine M.M., Galen J., Tacket C.O., Barry E.M., Pasetti F., Sztein M.B. Attenuated strains of Salmonella enterica serovar Typhi as live oral vaccines against typhoid fever. New generation vaccines 2004, Marcel Dekker, Inc., New York. M.M. Levine, J.B. Kaper, R. Rappuoli, M.A. Liu, M.F. Good (Eds.).
180. Alto N.M., Shao F., Lazar C.S., Brost R.L., Chua G., Mattoo S., et al. Identification of a bacterial type III effector family with G protein mimicry functions. Cell 2006, 124:133-145.
181. Garcia-del Portillo F., Zwick M.B., Leung K.Y., Finlay B.B. Salmonella induces the formation of filamentous structures containing lysosomal membrane glycoproteins in epithelial cells. Proc Natl Acad Sci U S A 1993, 90:10544-10548.
182. Mills S.D., Ruschkowski S.R., Stein M.A., Finlay B.B. Trafficking of porin-deficient Salmonella typhimurium mutants inside HeLa cells: ompR and envZ mutants are defective for the formation of Salmonella-induced filaments. Infect Immun 1998, 66:1806-1811.
183. Petrovska L., Aspinall R.J., Barber L., Clare S., Simmons C.P., Stratford R., et al. Salmonella enterica serovar Typhimurium interaction with dendritic cells: impact of the sifA gene. Cell Microbiol 2004, 6:1071-1084.
184. Michael A., Stratford R., Khan S., Dalgleish A., Pandha H. Novel strains of Salmonella typhimurium as potential vectors for gene delivery. FEMS Microbiol Lett 2004, 238:345-351.
185. Mestas J., Hughes C.C. Of mice and not men: differences between mouse and human immunology. J Immunol 2004, 172:2731-2738.
186. Gibbons D.L., Spencer J. Mouse and human intestinal immunity: same ballpark, different players; different rules, same score. Mucosal Immunol 2011, 4:148-157.
187. Mian M.F., Pek E.A., Chenoweth M.J., Coombes B.K., Ashkar A.A. Humanized mice for Salmonella typhi infection: new tools for an old problem. Virulence 2011, 2:248-252.
188. Firoz Mian M., Pek E.A., Chenoweth M.J., Ashkar A.A. Humanized mice are susceptible to Salmonella typhi infection. Cell Mol Immunol 2011, 8:83-87.
189. null mice are susceptible to lethal Salmonella Typhi infection. Proc Natl Acad Sci U S A 2010, 107:15589-15594.
190. Song J., Willinger T., Rongvaux A., Eynon E.E., Stevens S., Manz M.G., et al. A mouse model for the human pathogen Salmonella typhi. Cell Host Microbe 2010, 8:369-376.
191. Touze T., Tran A.X., Hankins J.V., Mengin-Lecreulx D., Trent M.S. Periplasmic phosphorylation of lipid A is linked to the synthesis of undecaprenyl phosphate. Mol Microbiol 2008, 67:264-277.